Ireland
--:--IST
Recruiting Not applicable

Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy

NCT06602843 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2024-01-01
Last updated
2024-09-19

Condition(s) studied

Esophageal Squamous Cell Carcinoma

Investigational drug(s) / intervention(s)

Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy

Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy: Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy

Study summary

The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Ages 18-75; * Radical operation for esophageal cancer; * Esophageal squamous cell carcinoma was confirmed by postoperative pathology; . Preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation were performed, and the stage was pIIB-IVA (AJCC eighth edition staging criteria: T≥3 or N+). * More than or equal to 12 lymph nodes were surgically removed; * Postoperative ECOG score 0-1, able to tolerate postoperative adjuvant radiotherapy and immunotherapy; * Informed consent signed by patient or family member. Exclusion Criteria: * Less than 18 years old, more than 75 years old; * did not receive radical resection of esophageal cancer, including palliative resection; * Postoperative pathology showed non-esophageal squamous cell carcinoma; * After preoperative imaging (enhanced cervical, thoracoabdominal CT+ bone scan) and postoperative pathological evaluation, the stage was pI, IIA, IVB (AJCC eighth edition staging standard); e. Less than 12 lymph nodes were surgically removed; * Postoperative ECOG score 2-3 points, unable to tolerate postoperative adjuvant radiotherapy and immunotherapy; * The patient or family member did not sign the informed consent.

Primary outcome measure(s)

  • pCR — immediately after the intervention/procedure/surgery
    Pathologic Complete Response

Trial sites (1)

FacilityCityRegionStatus
Anhui provincial hospital Hefei China Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06602843 on ClinicalTrials.gov ↗ ← All trials in China